- Home
- ANNX vs SATL Comparison
ANNX vs SATL Comparison
Compare ANNX & SATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- SATL
- Stock Information
- Founded
- ANNX 2011
- SATL 2010
- Country
- ANNX United States
- SATL United States
- Employees
- ANNX N/A
- SATL N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- SATL Radio And Television Broadcasting And Communications Equipment
- Sector
- ANNX Health Care
- SATL Technology
- Exchange
- ANNX Nasdaq
- SATL Nasdaq
- Market Cap
- ANNX 362.4M
- SATL 433.8M
- IPO Year
- ANNX 2020
- SATL N/A
- Fundamental
- Price
- ANNX $1.46
- SATL $3.89
- Analyst Decision
- ANNX Strong Buy
- SATL
- Analyst Count
- ANNX 5
- SATL 0
- Target Price
- ANNX $18.67
- SATL N/A
- AVG Volume (30 Days)
- ANNX 2.2M
- SATL 658.1K
- Earning Date
- ANNX 05-12-2025
- SATL 04-29-2025
- Dividend Yield
- ANNX N/A
- SATL N/A
- EPS Growth
- ANNX N/A
- SATL N/A
- EPS
- ANNX N/A
- SATL N/A
- Revenue
- ANNX N/A
- SATL $12,870,000.00
- Revenue This Year
- ANNX N/A
- SATL N/A
- Revenue Next Year
- ANNX N/A
- SATL N/A
- P/E Ratio
- ANNX N/A
- SATL N/A
- Revenue Growth
- ANNX N/A
- SATL 27.75
- 52 Week Low
- ANNX $1.29
- SATL $0.72
- 52 Week High
- ANNX $7.85
- SATL $5.49
- Technical
- Relative Strength Index (RSI)
- ANNX 30.77
- SATL 52.87
- Support Level
- ANNX $1.40
- SATL $3.73
- Resistance Level
- ANNX $1.68
- SATL $4.22
- Average True Range (ATR)
- ANNX 0.18
- SATL 0.40
- MACD
- ANNX 0.00
- SATL 0.04
- Stochastic Oscillator
- ANNX 19.13
- SATL 58.60
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.